# Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants

> **NCT07174830** · PHASE4 · RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Allisartan Isoproxil Tablets 240mg or placebo
- **DRUG:** Allisartan Isoproxil Tablets 480mg or placebo
- **DRUG:** Allisartan Isoproxil Tablets 720mg or placebo

## Key facts

- **NCT ID:** NCT07174830
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-06
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-02-16
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174830, "Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07174830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*